A proof of Pyber's base size conjecture

Building on earlier papers of several authors, we establish that there exists a universal constant c>0 such that the minimal base size b(G) of a primitive permutation group G of degree n satisfies log⁡|G|/log⁡n≤b(G)1 we have the estimates |G|

AIDS knowledge and attitudes in a Turkish population: an epidemiological study

BACKGROUND: The aim of this study was to investigate and present some pertinent comments concerning Acquired Immunodeficiency Syndrome (AIDS) knowledge, attitudes and misconceptions among the general population in a city of west Turkey. This study was deemed important and relevant due to the increasing importance of AIDS in Turkey and the other countries. METHODS: Using a multistage area sampling method, a random sample of individuals aged 11–83 years, living in 65 different quarters in the city of Eskisehir, Turkey during September, October and November 2004 were interviewed. RESULTS: In all, 1048 respondents completed the survey. In most items, respondents displayed a fairly good to excellent degree of knowledge about HIV/AIDS. Individuals with higher degrees of education indicated more correct responses in all items relating to knowledge of HIV/AIDS. In general, the respondents' attitudes towards AIDS and people with AIDS were found to be tolerant and positive, with one answer choice showing that the majority of the respondents agreed with the statement that those with HIV/AIDS must be supported, treated and helped (90.7%). Moreover, the proportions of the respondents' misconceptions were found to be significantly low for all the items. However, nearly one fourth of the respondents agreed with the misconceptions 'AIDS is a punishment by God' and 'One is not infected with HIV/AIDS if engaged in sport and well nourished'. CONCLUSION: In general HIV/AIDS related knowledge was high and people showed positive attitudes. However, people continue to hold misconceptions about AIDS and these need to be addressed by health education programs targeting those at higher risk

Performance of the NOνA Data Acquisition and Trigger Systems for the full 14 kT Far Detector

The NOvA experiment uses a continuous, free-running, dead-timeless data acquisition system to collect data from the 14 kT far detector. The DAQ system readouts the more than 344,000 detector channels and assembles the information into an raw unfiltered high bandwidth data stream. The NOvA trigger systems operate in parallel to the readout and asynchronously to the primary DAQ readout/event building chain. The data driven triggering systems for NOvA are unique in that they examine long contiguous time windows of the high resolution readout data and enable the detector to be sensitive to a wide range of physics interactions from those with fast, nanosecond scale signals up to processes with long delayed coincidences between hits which occur at the tens of milliseconds time scale. The trigger system is able to achieve a true 100% live time for the detector, making it sensitive to both beam spill related and off-spill physics

Raw data for the paper: Biphasic biocatalysis using a CO2-switchable Pickering emulsion

This file contains the Figures and Schemes in Green Chem., 2019, 21, 4062 as well as an excel file containing the following raw data: conversion of the reaction in Pickering emulsions under different conditions, conversion at various surfactant and enzyme concentrations, yield of the reaction and effect of the oil:water ratio on the conversion of the reaction

Structure–Activity Relationships and Discovery of (<i>S</i>)‑6-Isopropyl-2-methoxy-3-(3-methoxypropoxy)-10-oxo-5,10-dihydro‑6<i>H</i>‑pyrido[1,2‑<i>h</i>][1,7]naphthyridine-9-carboxylic Acid (AB-452), a Novel Orally Available HBV RNA Destabilizer

Approved therapies for hepatitis B virus (HBV) treatment include nucleos(t)ides and interferon alpha (IFN-α) which effectively suppress viral replication, but they rarely lead to cure. Expression of viral proteins, especially surface antigen of the hepatitis B virus (HBsAg) from covalently closed circular DNA (cccDNA) and the integrated genome, is believed to contribute to the persistence of HBV. This work focuses on therapies that target the expression of HBV proteins, in particular HBsAg, which differs from current treatments. Here we describe the identification of AB-452, a dihydroquinolizinone (DHQ) analogue. AB-452 is a potent HBV RNA destabilizer by inhibiting PAPD5/7 proteins in vitro with good in vivo efficacy in a chronic HBV mouse model. AB-452 showed acceptable tolerability in 28-day rat and dog toxicity studies, and a high degree of oral exposure in multiple species. Based on its in vitro and in vivo profiles, AB-452 was identified as a clinical development candidate

Structure–Activity Relationships and Discovery of (<i>S</i>)‑6-Isopropyl-2-methoxy-3-(3-methoxypropoxy)-10-oxo-5,10-dihydro‑6<i>H</i>‑pyrido[1,2‑<i>h</i>][1,7]naphthyridine-9-carboxylic Acid (AB-452), a Novel Orally Available HBV RNA Destabilizer

Approved therapies for hepatitis B virus (HBV) treatment include nucleos(t)ides and interferon alpha (IFN-α) which effectively suppress viral replication, but they rarely lead to cure. Expression of viral proteins, especially surface antigen of the hepatitis B virus (HBsAg) from covalently closed circular DNA (cccDNA) and the integrated genome, is believed to contribute to the persistence of HBV. This work focuses on therapies that target the expression of HBV proteins, in particular HBsAg, which differs from current treatments. Here we describe the identification of AB-452, a dihydroquinolizinone (DHQ) analogue. AB-452 is a potent HBV RNA destabilizer by inhibiting PAPD5/7 proteins in vitro with good in vivo efficacy in a chronic HBV mouse model. AB-452 showed acceptable tolerability in 28-day rat and dog toxicity studies, and a high degree of oral exposure in multiple species. Based on its in vitro and in vivo profiles, AB-452 was identified as a clinical development candidate